Haleon plc (NYSE:HLN) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its holdings in Haleon plc (NYSE:HLN - Free Report) by 30.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 265,744 shares of the company's stock after purchasing an additional 62,161 shares during the period. Charles Schwab Investment Management Inc.'s holdings in Haleon were worth $2,535,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HLN. Sierra Ocean LLC bought a new position in Haleon in the fourth quarter worth about $26,000. Versant Capital Management Inc grew its position in shares of Haleon by 2,029.1% in the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company's stock worth $34,000 after buying an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Haleon during the 4th quarter worth approximately $35,000. Toronto Dominion Bank lifted its position in Haleon by 3,470.0% during the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company's stock valued at $38,000 after acquiring an additional 3,470 shares during the last quarter. Finally, Spire Wealth Management acquired a new stake in Haleon in the fourth quarter valued at approximately $39,000. 6.67% of the stock is currently owned by institutional investors.

Haleon Stock Performance

Shares of HLN stock traded down $0.02 during mid-day trading on Wednesday, reaching $10.16. The stock had a trading volume of 7,631,954 shares, compared to its average volume of 6,593,751. Haleon plc has a 1-year low of $7.99 and a 1-year high of $10.80. The firm has a market cap of $46.00 billion, a price-to-earnings ratio of 29.88, a PEG ratio of 2.82 and a beta of 0.25. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The business's fifty day moving average is $10.00 and its 200-day moving average is $9.87.

Haleon (NYSE:HLN - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. On average, research analysts forecast that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The firm also recently announced a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be given a dividend of $0.1166 per share. The ex-dividend date is Friday, April 25th. This is an increase from Haleon's previous -- dividend of $0.05. This represents a yield of 1.6%. Haleon's payout ratio is currently 58.97%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on HLN shares. Sanford C. Bernstein downgraded Haleon from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Hsbc Global Res downgraded Haleon from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. Morgan Stanley downgraded shares of Haleon from an "overweight" rating to an "equal weight" rating in a report on Friday, January 10th. Finally, HSBC reaffirmed a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Six research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.